FT Options’s United Therapeutics UTHR Stock Holding History

FT Options’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-21,400	Closed	-$77K	–	295
2017 Q1	$77K	Hold	21,400	–	–	0.1%	129
2016 Q4	$124K	Buy	21,400 +400	+2%	+$51.1K	0.14%	89
2016 Q3	$385K	Buy	+21,000	New	+$2.52M	0.31%	67
2016 Q1	–	Sell	-50,000	Closed	-$53K	–	346
2015 Q4	$53K	Buy	+50,000	New	+$7.28M	0.04%	152

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

FT Options's UTHR Position: Q2 2017 in Review

FT Options sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 9,723 shares — an estimated $1.32M sold.

FT Options first reported a position in UTHR in Q4 2015 and held it in 4 quarters. The position peaked at $2.08M in Q4 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

FT Options reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
FT Options sold 9,723 United Therapeutics shares in Q2 2017, an estimated $1.32M.
FT Options first reported a position in United Therapeutics in Q4 2015 and held it in 4 quarters.
FT Options's United Therapeutics position peaked at $2.08M in Q4 2015.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.